Cargando…

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report

BACKGROUND: Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer. To date, no report about poly(ADP-ribose) polymerase inhibitors has been published on cervical cancer. CASE PR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montero-Macias, Rosa, Koual, Meriem, Crespel, Céline, Le Frére-Belda, Marie Aude, Hélène, Hélène Blons, Nguyen-Xuan, Huyen-Thu, Garinet, Simon, Perkins, Géraldine, Balay, Vincent, Durdux, Catherine, Florin, Marie, Péré, Hélène, Bats, Anne-Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063354/ https://www.ncbi.nlm.nih.gov/pubmed/33888155 http://dx.doi.org/10.1186/s13256-021-02767-9

Ejemplares similares

Updated Prognostic Factors in Localized NSCLC
por: Garinet, Simon, et al.
Publicado: (2022)

HPV Molecular Genotyping as a Differential Diagnosis Tool in Cervical Cancer Metastasis
por: Montero-Macías, Rosa, et al.
Publicado: (2023)

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
por: Garinet, Simon, et al.
Publicado: (2018)

Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
por: Perrier, Alexandre, et al.
Publicado: (2020)

Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
por: Bayle, Arnaud, et al.
Publicado: (2021)

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency
por: Pallet, Nicolas, et al.
Publicado: (2020)

Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data
por: Seidler, Stephanie, et al.
Publicado: (2021)

Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis
por: Lelong, Margaux, et al.
Publicado: (2022)

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors
por: Medioni, Jacques, et al.
Publicado: (2012)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

MEM: An Algorithm for the Reliable Detection of Microsatellite Instability (MSI) on a Small NGS Panel in Colorectal Cancer
por: Herbreteau, Guillaume, et al.
Publicado: (2021)

Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2022)

Environmental chemicals, breast cancer progression and drug resistance
por: Koual, Meriem, et al.
Publicado: (2020)

Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer
por: Jiang, Yi-Ling, et al.
Publicado: (2023)

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial
por: Verstraete, M, et al.
Publicado: (2015)

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
por: Marijon, Hélène, et al.
Publicado: (2021)

A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma
por: Garinet, Simon, et al.
Publicado: (2023)

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
por: Dean, E, et al.
Publicado: (2012)

Short-term outcome of patients with preeclampsia
por: Koual, Meriem, et al.
Publicado: (2013)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
por: Varanda, Ana Beatriz, et al.
Publicado: (2020)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer
por: Métairie, Marie, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
por: Lee, Yong Jae, et al.
Publicado: (2021)

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)
por: Kim, Se Ik, et al.
Publicado: (2021)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2018)

Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
por: Paulino, Eduardo, et al.
Publicado: (2020)

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines
por: Witz, Andréa, et al.
Publicado: (2023)

Food Provisioning and Parental Status in Songbirds: Can Occupancy Models Be Used to Estimate Nesting Performance?
por: Corbani, Aude Catherine, et al.
Publicado: (2014)

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
por: Xie, Yuan, et al.
Publicado: (2016)

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2
por: Rytelewski, Mateusz, et al.
Publicado: (2016)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

Author Correction: Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2018)

Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial
por: Lee, Nancy Y., et al.
Publicado: (2023)

The Role of the Kynurenine/AhR Pathway in Diseases Related to Metabolism and Cancer
por: Shadboorestan, Amir, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jgb2cfld1drr0dgfeb3jjkeamq